GlobalData on MSN5d
Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema
The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.
Zacks.com on MSN5d
NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate
Intellia doses the first patient in the phase III HAELO study on NTLA-2002 for treating hereditary angioedema. Stock rises.
Intellia Therapeutics announces first patient dosed in Phase 3 NTLA-2002
Intellia Therapeutics (NTLA) announced the first patient has been dosed in the global Phase 3 study of NTLA-2002 for the treatment of ...
Nasdaq6d
Intellia Therapeutics Doses First Patient in Global Phase 3 Study of NTLA-2002 for Hereditary Angioedema Treatment
Intellia Therapeutics, Inc. announced the dosing of the first patient in the global Phase 3 study for NTLA-2002, a CRISPR-based therapy aimed at treating hereditary angioedema (HAE). This ...
Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Lowered by Morgan Stanley
Morgan Stanley lowered shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) from an overweight rating to an equal ...
Intellia Jumps on Test Announcement
Intellia Therapeutics, Inc. (NASDAQ:NTLA) shares acquire momentum first thing. The Cambridge, Mass.-based Intellia, a leading clinical-stage gene editing company focused on revolutionizing medicine ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Intellia Therapeutics, Inc - NTLA
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Intellia ...
Stockhouse6d
NTLA ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Intellia Therapeutics, Inc. Shareholders Who Lost Money
Among other items, Intellia announced that it plans to focus its resources on developing drug candidates NTLA-2002 and nex-z and will discontinue development of NTLA-3001, which will result in the ...